<DOC>
	<DOC>NCT02872857</DOC>
	<brief_summary>The purpose of this study is to examine the effects of the study drug--Galantamine—on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.</brief_summary>
	<brief_title>Subarachnoid Hemorrhage Recovery And Galantamine</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Spontaneous subarachnoid hemorrhage Presentation to hospital within 24 hours of symptoms Fisher grade 3 hemorrhage (thick subarachnoid clot) on initial computed tomography (CT) scan Hunt and Hess grade 25 at time of randomization Presence of a saccular aneurysm on computed tomographic angiography (CTA) or Angiogram for which clipping or coiling is possible Ability to obtain medication within 36 hours of presentation subarachnoid hemorrhage (SAH) due to causes other than aneurysm rupture (trauma, arteriovenous malformation (AVM), mycotic aneurysms, Moyamoya) Preexisting disability with modified Rankin Scale (mRS) score ≥2, Renal disease as defined by creatinine clearance less than 9 milliliters/min History of severe hepatic impairment (ChildPugh score of 1015) History of chronic obstructive pulmonary disease (COPD) or asthma History of dementia Comorbid conditions likely to complicate therapy, including clinically significant arrhythmia, acquired immune deficiency syndrome (AIDS), autoimmune disease, malignancy, and expected mortality within 72 hours Expected mortality within 72 hours as determined by PI, treating neurointensivist and neurosurgeon. (Clinically manifested by no attempt at securing aneurysm) Females who are pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>